ACC 2021: AstraZeneca's Farxiga failed to help COVID-19 patients, but it’s safe for them to use

As doctors faced the novel coronavirus without an arsenal early last year, AstraZeneca wondered whether its diabetes drug Farxiga could help prevent organ failure and death among the most vulnerable COVID-19 patients. Because the oral SGLT2 inhibitor can protect organs in people with Type 2 diabetes, heart failure and chronic kidney disease, it might do the same for at-risk patients hospitalized with the virus, or so the thinking went.